Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
about
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesBispecific T-cell engagers for cancer immunotherapy.Are BiTEs the "missing link" in cancer therapy?CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaChimeric antigen receptor T cells for sustained remissions in leukemiaImpact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110Blinatumomab and Pembrolizumab.Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.Improving the outcome for children with cancer: Development of targeted new agents.Paediatric non-Hodgkin lymphoma - perspectives in translational biologyAntibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Immune-based therapies for childhood cancer.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Blinatumomab: first global approval.The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.Current status of chimeric antigen receptor therapy for haematological malignancies.Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.A review of blinatumomab, a novel immunotherapy.A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Immunotherapy approaches to treat adult acute lymphoblastic leukemia.Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.Emerging biological therapies to treat acute lymphoblastic leukemia.Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).Novel therapy for childhood acute lymphoblastic leukemia.Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.Blinatumomab-associated vasculitisTyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.Recent advances in the management of pediatric acute lymphoblastic leukemia.
P2860
Q26764903-8FCDD8BD-BD39-49F4-8218-BFFB7605FF64Q26775363-F5A0D55D-01DC-4FAB-97AB-D572705090B7Q26796313-A273B8D5-377A-44F1-A906-ED14FEF3E8F0Q26828511-726F16F2-E8C1-4274-9BAF-0AC096DB79F0Q26865838-AD639F44-17BC-494B-911C-62D217FEB841Q27693313-CC3962FA-3A74-4DDF-9438-9F784AC646EEQ28083907-6B787A1D-E489-46FD-936C-0134B538A657Q28084879-303D4D3A-F240-4631-B91B-9B1BB670261CQ29617588-E7CEB976-2C7D-4C8A-B83A-4F1782AB745EQ35824663-859C0ACD-486D-45BD-8470-CD2F7A1FBE1CQ36110034-AFCE2727-9950-4BC6-B34C-F5F941E0FE47Q36169572-BF437B98-99A1-463B-9727-EAB75187AE74Q36238795-3E16C90D-6159-42A9-B1C1-2E20FD7016D8Q36889143-7C82079C-46A3-4951-AC7B-D8E2F66AAEC8Q38224988-627B2D30-081A-4C66-AB5B-4929CE3A8C81Q38263108-A9ED96B5-4FFD-423B-A0B7-B9F22E1D1ADFQ38289029-D0CEE03D-FF01-4F36-B36D-EDA0C11AE5D0Q38338407-4CC285A7-B3A6-4143-AE67-B1CFC02C0723Q38460308-BCFC640C-EC5F-4867-B351-0323ECCDBA65Q38515225-B0D16DC5-D04B-4564-A01D-820D5CC9BAD2Q38631108-30E88E17-5A51-4C5F-9598-47C34D1B0800Q38639698-6D144514-B475-431A-B967-8EB2CDE8E37CQ38647682-A413E186-DAB7-4928-9689-23E9573DAD49Q38674589-9B546FEE-9752-4CDB-921E-83B3C73B80A1Q38698520-9D6A15A6-B383-421F-BEA4-055EB09FAB50Q38728592-826B1285-8E9D-4DE3-876A-3BCB143B7463Q38759754-FAAAE318-07E7-4A9E-838C-9BA0EA78E2CEQ38787405-C6AED575-FFCB-490F-BEC3-4C8532AD6C1CQ38799449-9A2C5AEB-80DD-4D76-B73F-B964E26A6077Q38803361-14BAC68D-B66F-42A6-BC7C-A98EA854B9FCQ38813257-E2C5DE8F-6A9E-4D4A-B4EB-C64A497E0471Q38814436-7A9C7982-176B-4CD1-ADD6-60BF900F4928Q38912282-F19D329A-527B-4DCB-90D4-9E67588B904DQ39002036-CFC2B06C-8D6D-4C33-B75D-BF8A3D810D97Q39005635-8A63A4BF-5F61-4F96-A483-C82F40035B38Q39368957-033CF4BA-B31D-461A-AAF4-4912B7076548Q41149154-9D680797-9FBC-4005-8EF9-69DA865BB419Q41597386-53716B0A-F72D-4BA2-A9CB-96E253124636Q43175147-C21532BE-63C1-4B3D-9575-E647AB53DBA3Q45105040-E8680413-F159-45D4-BF5C-0718C13DB7A3
P2860
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@ast
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@en
type
label
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@ast
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@en
prefLabel
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@ast
Pediatric posttransplant relap ...... pecific antibody blinatumomab.
@en
P2093
P2860
P1433
P1476
Pediatric posttransplant relap ...... specific antibody blinatumomab
@en
P2093
Christina Kyzirakos
Gerhard Zugmaier
Heiko-Manuel Teltschik
Hermann Kreyenberg
Judith Feucht
Kai-Erik Witte
Patrick Schlegel
Peter Lang
Rupert Handgretinger
Tobias Feuchtinger
P2860
P304
P356
10.3324/HAEMATOL.2013.100073
P577
2014-04-11T00:00:00Z